MOUNTAIN VIEW, Calif.,
Oct. 20 /PRNewswire-FirstCall/ --MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will present nine analyses relating to its LEVADEX™ orally
inhaled migraine therapy product candidate, including analysis from
the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and
Migraine Trust International Congress (EHMTIC) in Nice, France. EHMTIC is a biennial
congress of the Migraine Trust and the European Headache Federation
for neurologists, physicians, scientists, researchers,
international experts and healthcare professionals.
An oral platform presentation titled "Utility of LEVADEX in
Situations Where Early Intervention Paradigm is Impractical"
reports the efficacy of LEVADEX in treating acute migraine at
different time points during an attack, as early as initial
migraine onset and as late as eight hours after onset of a migraine
attack. It will be presented by Stewart
Tepper, M.D., Director of Research for the Center for
Headache and Pain at the Cleveland Clinic during the
Migraine-Clinical Experiment Studies session on Sunday, October 31 at 10:40 a.m. CEST. This will also be presented as a
poster (#322) starting Saturday, October
30 at 9:00 a.m. CEST.
In addition, two new analyses from the LEVADEX program will be
presented in poster presentations. Poster number 460, "The Major
Metabolite of Dihydroergotamine (DHE) After Oral Inhalation and IV
Administration Does Not Significantly Contribute to the
Pharmacological Activity," will be presented starting Thursday, October 28 at 12:00 p.m. CEST. Poster number 471, "Migraine
Recurrence Rates: Case for Standardization of the Definition," will
be presented starting Saturday, October
30 at 9:00 a.m. CEST.
Six additional poster presentations also will be presented in
two separate sessions:
Thursday, October 28 at
12:00 p.m. CEST
- Efficacy Evaluation of LEVADEX in Treating a Broad Spectrum of
Acute Migraine Attacks (#463)
- Evaluation of Safety and Efficacy of LEVADEX (MAP0004) in
Treating Acute Menstrual Migraine (#465)
- Evaluation of Efficacy and Safety of LEVADEX (MAP0004) in
Reversing Central Sensitization and Treating Migraine in
Established Allodynic Patients (#466)
Saturday, October 30 at
9:00 a.m. CEST
- LEVADEX, a Novel Orally Inhaled Treatment for Acute Migraine:
Efficacy and Tolerability Results of a Phase 3 Study (#462)
- Efficacy Evaluation of LEVADEX in Treating Resistant Migraine
Including Migraine with Allodynia, Morning Migraine, Disabling
Migraine and Migraine Treated Late (#464)
- The Efficacy and Tolerability of LEVADEX (Orally Inhaled DHE)
for the Treatment of Migraine in Subjects with Concomitant Asthma
(#467)
About LEVADEX™
LEVADEX orally inhaled migraine therapy is a novel migraine
therapy in Phase 3 development. Patients administer LEVADEX
themselves using the company's proprietary TEMPO® inhaler. LEVADEX
has been designed to be differentiated from existing migraine
treatments. It is a novel formulation of dihydroergotamine (DHE), a
drug used intravenously in clinical settings to effectively and
safely treat migraines. Based on clinical results, the company
believes that LEVADEX has the potential to provide both fast onset
of action, sustained pain relief and other migraine symptom relief
in an easy-to-use and non-invasive at-home therapy.
LEVADEX is designed to incorporate the multiple beneficial
mechanisms of action that allow DHE to block initiation of
migraine, limit pain, reduce inflammation and stop a migraine at
any point in the migraine cycle. Based on research to date,
including the efficacy portion of the FREEDOM-301 trial, the
company believes the unique pharmacokinetic profile of LEVADEX has
the potential to effectively treat migraines, while minimizing the
side effects commonly seen with DHE and other currently available
medicines.
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and
commercializing new therapies for patients suffering from
conditions that are not adequately treated by currently available
medicines. The Company is developing LEVADEX inhaled therapy for
the potential treatment of migraine and has reported positive
results from the efficacy portion of its Phase 3 trial of LEVADEX.
In addition, MAP Pharmaceuticals generates new pipeline
opportunities by applying its proprietary drug particle and
inhalation technologies to enhance the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of
current conditions, this press release contains forward-looking
statements, including with respect to MAP Pharmaceuticals' LEVADEX
product candidate. Actual results may differ materially from
current expectations based on risks and uncertainties affecting the
Company's business, including, without limitation, risks and
uncertainties relating to the conduct and completion of clinical
trials, and relating to the preparation and filing of a New Drug
Application and the regulatory process to have the Company's
LEVADEX product candidate approved for commercial use. The reader
is cautioned not to unduly rely on the forward-looking statements
contained in this press release. MAP Pharmaceuticals expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law. Additional information on
potential factors that could affect MAP Pharmaceuticals' results
and other risks and uncertainties are detailed in its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2010, available at
http://edgar.sec.gov.
CONTACTS:
|
|
Nicole
Foderaro
|
|
WCG
|
|
(415)
946-1058
|
|
nfoderaro@wcgworld.com
|
|
|
SOURCE MAP Pharmaceuticals, Inc.
Copyright . 20 PR Newswire